Dr. Müller is Professor of Addiction Medicine at the Friedrich-Alexander-University Erlangen-Nuremberg, Germany. He obtained his PhD in Psychology from the University of Düsseldorf. He did PostDocs at the University of Syracuse (USA), University of Düsseldorf, and University of Brasilia (Brazil) before becoming a Senior Lecturer at the Institute of Psychiatry, King’s College London, UK. In 2010 he joined the Friedrich-Alexander-University of Erlangen-Nuremberg, Germany. He serves on several journal editorial boards and guest edited special issues of Behavioral Brain Research and Brain Research Bulletin. Dr. Müller has published more than 120 scientific papers and book chapters. Kathryn A. Cunningham is a pharmacologist and neuroscientist with a focus on advancing the biological understanding of psychiatric disorders and developing effective and safe therapeutics to maximize human function. Her cross-disciplinary, translational research efforts with chemists, cell biologists and clinical scientists are focused on pinpointing the critical roles of two serotonin proteins (5-HT2A and 5-HT2C receptors) in substance use disorder and the discovery of novel medications to extend abstinence. Her research has been funded continuously for 26 years, has led to three patents for new chemical entities and over 150 publications. Her research and educational contributions have been recognized by the American Society for Pharmacology and Experimental Therapeutics-Astellas Award for Translational Pharmacology and the Marian Fischman Memorial Award and the Mentorship Award from the College on Problems of Drug Dependence. Dr. Cunningham is the author of nearly 150 scientific publications and is currently Associate Editor of ACS Chemical Neuroscience and of Nature Neuropsychopharmacology.